# Kern Venture Group

> Kern Venture Group is a VC fund in Bakersfield backing Health Care and Medical. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bakersfield, United States
- Total investments: 9
- Last investment: May 2026
- Lead investor: 11%
- Fund size: $2.2M
- Last fund: Oct 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kern-venture-group/
- X (Twitter): https://twitter.com/kernventuregrp/
- Website: http://kernvg.com
- Facebook: https://www.facebook.com/Kern-Venture-Group-334647497339359/

Kern Venture Group is a micro VC fund that targets early-stage investments in entrepreneurs who are looking to develop disruptive technology. Its investments offered is made in seed-stage startups, primarily in the tech and industrial sectors.

## Contacts

5 contacts available for Kern Venture Group. Shizune tracks 1 team members at Kern Venture Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kern-venture-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Medical | 3 | 33% |
| Medical Device | 3 | 33% |
| Mobile | 2 | 22% |
| Software | 2 | 22% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 33% |
| Pre-Seed | 2 | 22% |
| Series A | 1 | 11% |
| Series B | 1 | 11% |
| Funding Round | 1 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 67% |
| Canada | 1 | 11% |
| United Kingdom | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Higdon | Co-Founder & Fund Manager | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kordata Dynamics | Kordata Dynamics is a neurotech‑focused clinical trial company that builds an AI‑powered digital platform to enable “next‑generation precision clinical trials,” particularly in central‑nervous‑system and related therapeutic areas. |  | Pre-Seed | May 21, 2026 |  |
| ChurchAI | The Intelligent OS For Churches. | $1.3M | Pre-Seed | May 21, 2026 |  |
| DermaSensor | DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $16M | Series B | Oct 02, 2025 |  |
| MIMOSA Diagnostics | MIMOSA Diagnostics is the maker of the MIMOSA Pro, a handheld device that uses near-infrared light to accurately and non-invasively assess tissue health. It can be easily used by a patient or a caregiver, and the images produced will help inform the next steps within patient navigation and management |  | Venture - Series Unknown | Jun 12, 2024 |  |
| BIOS | BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). |  | Venture - Series Unknown | Jan 09, 2024 |  |
| Cambium | Cambium develops biomaterials for fields such as defense, space transport, aerospace, and renewable energy. Leveraging the Deep Tech convergence between synthetic biology, materials science, computation & automation, it delivers radical step changes in advanced material performance and sustainability to improve today’s products and enabletomorrow’s. | $19M | Series A | Dec 05, 2023 |  |
| Measure Studio | Measure Studio is an engine designed to create a social media content strategy that is informed by data. Digital publishers, companies, agencies, and influencers may consolidate and analyze their social media data using the company's engine in order to create better content. The engine offers a safe environment for managing social mediaanalytics. |  | Seed | Apr 21, 2023 |  |
| Autio | HearHere is a travel audio app that shares the depth and diversity of stories - cultural, geographical, historical, and mythological. | $2.4M | Seed | Mar 29, 2023 |  |
| Sigo Seguros | Sigo uses data and automation to provide lower-cost policies for the Latino market. | $5.4M | Seed | Apr 07, 2022 |  |

9 of 9 investments shown.

## Co-investors
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 1 deal together
- [Allied Venture Partners](https://shizune.co/investors/profile/allied-venture-partners) — VC Fund, 1 deal together
- [blue 9 capital](https://shizune.co/investors/profile/blue-9-capital) — VC Fund, 1 deal together
- [Chingona Ventures](https://shizune.co/investors/profile/chingona-ventures) — VC Fund, 1 deal together
- [iHeartMedia](https://shizune.co/investors/profile/clear-channel-communications) — VC Fund, 1 deal together
- [Cooley](https://shizune.co/investors/profile/cooley-llp) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Kern Venture Group invest in?

Kern Venture Group invests primarily in Health Care, Medical and Medical Device startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kern Venture Group?

Public channels for Kern Venture Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kern Venture Group?

The team at Kern Venture Group includes David Higdon (Co-Founder & Fund Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co